- Home
- AHG vs KALV Comparison
AHG vs KALV Comparison
Compare AHG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- KALV
- Stock Information
- Founded
- AHG 2013
- KALV N/A
- Country
- AHG China
- KALV United States
- Employees
- AHG N/A
- KALV N/A
- Industry
- AHG Business Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- KALV Health Care
- Exchange
- AHG Nasdaq
- KALV Nasdaq
- Market Cap
- AHG 939.1M
- KALV 796.4M
- IPO Year
- AHG N/A
- KALV N/A
- Fundamental
- Price
- AHG $1.83
- KALV $14.42
- Analyst Decision
- AHG
- KALV Strong Buy
- Analyst Count
- AHG 0
- KALV 8
- Target Price
- AHG N/A
- KALV $26.29
- AVG Volume (30 Days)
- AHG 9.1K
- KALV 901.7K
- Earning Date
- AHG 09-12-2025
- KALV 09-11-2025
- Dividend Yield
- AHG N/A
- KALV N/A
- EPS Growth
- AHG N/A
- KALV N/A
- EPS
- AHG N/A
- KALV N/A
- Revenue
- AHG $14,777,798.00
- KALV $1,426,000.00
- Revenue This Year
- AHG N/A
- KALV N/A
- Revenue Next Year
- AHG N/A
- KALV $221.95
- P/E Ratio
- AHG N/A
- KALV N/A
- Revenue Growth
- AHG 512.09
- KALV N/A
- 52 Week Low
- AHG $0.74
- KALV $7.30
- 52 Week High
- AHG $2.35
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- AHG 55.43
- KALV 52.54
- Support Level
- AHG $1.65
- KALV $13.26
- Resistance Level
- AHG $1.95
- KALV $17.28
- Average True Range (ATR)
- AHG 0.11
- KALV 0.93
- MACD
- AHG 0.00
- KALV 0.11
- Stochastic Oscillator
- AHG 65.71
- KALV 34.70
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.